Adicet Bio Q2 net loss $31.2M; discontinues ADI-270, cuts workforce 30%

Adicet Bio, Inc.

2025-Q2 EPS reported -$0.65 vs consensus -$4.97 ▲ beat (+86.9%)

Net loss $31.2M ($0.34/sh) vs $29.9M ($0.33/sh) in Q2 2024; R&D spending rose to $28.4M.
Cash $125.0M as of June 30, 2025, down from $176.3M at year-end 2024; runway into Q4 2026.
Discontinued ADI-270 for ccRCC; workforce reduced ~30% to extend cash runway.
Prioritizing ADI-212 (PSMA, prostate cancer); IND filing expected Q1 2026, data 2H 2026.
Phase 1 ADI-001 autoimmune trial expanded to IIM, SPS, AAV; preliminary data expected 2H 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.